Articles tagged "FK506"

2015 American Transplant Congress
Plasma 4β-Hydroxycholesterol Measurement as a Potential Biomarker for CYP3A5 Activity in Informing Tacrolimus Dosing
T. Elnahhas,^1,2 E. de Jonge,⁴ T. Lee,² B. van Zelst,⁴ J. Popoola,³ R. Ramkhelawon,³ R. van Schaik,⁴ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St.George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St.George's University of London, London, United Kingdom; ⁴Clinical Chemistry, Erasmus MC Rotterdam, Rotterdam, Netherlands.
Background—Recently, 4β-hydroxycholesterol (4β-OHC) has been shown to be an endogenous marker of P450 3A activity in clinical practice (Diczfalusy et al, 2011). 4β-OHC concentration increases…
2015 American Transplant Congress
Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations
T. Elnahhas,^1,2 T. Lee,² M. Moreton,² D. McKeown,² J. Popoola,³ R. Ramkhelawon,³ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology Department, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St.George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St.George's University of London, London, United Kingdom.
Background. Tacrolimus is available in two formulations, immediate-release, (Prograf®) and prolonged -release formulation of tacrolimus (Advagraf®). Tacrolimus has a narrow therapeutic index with wide variation…
2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
T. Hsu,¹ J. Yin,¹ L. Awdishu,¹ J. Kerr,¹ R. Steiner.²
¹Pharmacy, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla; ²Medicine, UC San Diego School of Medicine, La Jolla.
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…
2015 American Transplant Congress
Conversion from Immediate to Prolonged Release Tacrolimus Did Not Change Intra-Patient Variability in Renal Transplant Patients
T. El-Nahhas,^1,2 M. Moreton,² J. Popoola,³ S. Abat,³ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology Department, William Harvey Research Institute, Barts and The London, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St. George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St. George's University of London, London, United Kingdom.
Background. Tacrolimus has a narrow therapeutic index and is characterized by a large inter- and intra-patient variability (IPV). Variable blood tacrolimus concentrations have been shown…
2015 American Transplant Congress
Tacrolimus for the Treatment of Refractory Biopsy-Proven Acute Cellular Rejection in Patients on Belatacept-Based, CNI- and Steroid-Free Immunosuppression Regimens
K. Trobaugh,¹ A. Shields,^1,2 S. Tremblay,¹ R. Alloway,¹ M. Cardi,² D. Witte,¹ F. Paterno,¹ M. Cuffy,¹ E. Woodle.¹
¹Univ of Cincinnati, Cincinnati; ²The Christ Hospital, Cincinnati.
Background: Tacrolimus (TAC) is effective as rescue treatment (tx) in renal transplant patients (pts) on cyclosporine-based immunosuppression (IS) who have recurrent or resistant acute rejection…
2015 American Transplant Congress
Alemtuzumab Induction Is Protective Against Acute Rejection in Kidney Recipients With Subtherapeutic Tacrolimus Concentrations
K. Szempruch, R.-A. Lee, R. Dupuis, J. Deyo, T. Kozlowski.
Transplant Surgery, University of North Carolina Hospitals, Chapel Hill, NC.
Purpose: To determine the effect of attaining early therapeutic tacrolimus (TAC) trough concentrations on biopsy-proven acute rejection (BPAR) within 12 months post-transplantation in adult kidney…
2015 American Transplant Congress
Long-Term Follow-Up After Conversion from Twice-Daily Tacrolimus Formulation to Once-Daily Tacrolimus Formulation in Pediatric Kidney Transplantation
C. Choi, A. Han, S. Min, S.-K. Min, T. Lee, I.-M. Jung, S. Kim, J. Ha.
Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
PurposeTacrolimus is one of the most frequently used immunosuppressants in pediatric kidney transplantation (KT) as in adult. In Pediatric kidney recipients, it is more important…